US accountable care | Connect a medicines question to the right incentive

CMS describes the Medicare Shared Savings Program as coordinated provider care with quality and spending responsibilities (CMS, n.d.). That does not make an ACO equivalent to an NHS integrated care board or a prescription-drug plan. Our first discussion would establish the organisation’s programme, participants, decision authority and delivery partners. The buyer may be a population-health or pharmacy leader, but the person sponsoring the work must control the workflow being studied.

An introductory evaluation could review one existing pathway proposal, using authorised aggregate records and the organisation’s current service documents. It would compare a PHARMORIS-supported evidence and implementation brief with usual preparation. We would describe the responsible roles, required approvals, dependencies and untested assumptions. Any question about individual treatment or clinical effectiveness would require its own appropriate professional and research design beyond this operational preparation exercise.

CMS publishes programme guidance and quality specifications, which provide context for the participating organisation (CMS, n.d.). A local study still needs a defined population and a credible comparison. We would record inclusion rules, baseline period and concurrent changes. If a later prospective evaluation is proposed, the sponsor would need to decide how confounding, attribution and follow-up are handled. A before-and-after graph alone would not establish that the intervention caused a change.

We would stop or redesign if the decision sits outside the sponsor’s authority, the required participant organisations are not engaged or the data cannot support the stated comparison. A favourable opinion from one meeting would not justify a clinical claim. The pilot should report material omissions, disagreement and additional review effort as openly as any time saved. An inconclusive result can prevent a network from scaling an unsuitable process.

A next phase would require an operational benefit that users can verify and a buyer willing to fund a defined evaluation. Commercial scale would depend on repeatable work across organisations with similar needs, without treating programme participation as proof of demand. We would distinguish the cost of preparing decisions from any later health or expenditure outcome. That separation makes the business proposition easier to test and less dependent on an attractive but unearned savings narrative.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.